#United States #New York #Petrichor #Paul Sekhri #vTv Therapeutics

Petrichor Appoints Paul Sekhri as Operating Partner

Petrichor, a prominent player in the healthcare and life sciences investment scene, has recently announced the strategic appointment of Paul J. Sekhri as its new Operating Partner. This move is aimed at bolstering the firm's capability to support innovative healthcare initiatives.

Elevating Expertise in Life Sciences

Mr. Sekhri brings with him an impressive portfolio, boasting over 35 years of executive experience across diverse areas within the life sciences industry. His illustrious career spans significant leadership roles in multinational pharmaceutical corporations, venture-funded biotech companies, and top-tier venture capital and private equity institutions. This level of expertise positions him as a valuable asset for Petrichor as it aims to fuel advancements in health and medical technology.

Tadd Wessel, the Founder and Managing Partner at Petrichor, expressed his enthusiasm about Sekhri's addition to the team, stating, "We are incredibly fortunate to welcome Paul to the Petrichor family. His skills as a leader of life sciences companies, coupled with his extensive background as a CEO and Chairman of various boards, significantly enhance our capabilities to identify and support emerging healthcare innovators."

A Proven Track Record

Currently, Sekhri holds the position of Chairman, President, and CEO at vTv Therapeutics, Inc. His previous roles include President and CEO at eGenesis, Inc., where he made notable advancements in the field of xenotransplantation, a topic of great relevance considering the ongoing discussions about organ transplants. Furthermore, he led Lycera Corporation, focusing on biopharmaceuticals aimed at immune-mediated diseases, and founded Cerimon Pharmaceuticals, overseeing its growth from concept to operational success.

His impressive resume also includes senior roles in business development and strategy at renowned companies such as Sanofi, Teva Pharmaceutical Industries, TPG Biotech, ARIAD Pharmaceuticals, and Novartis AG. This varied experience across both biopharma giants and startup environments underlines his understanding of the challenges and needs of the sector.

Vision for Petrichor

In his own words, Mr. Sekhri has highlighted his admiration for the Petrichor team, stating, "I have seen firsthand how the Petrichor team helps innovative companies succeed in both transactional and operational settings. Petrichor has quickly become a uniquely thoughtful investor, leveraging the comprehensive perspective gained over the team’s decades of experience."

Sekhri’s involvement is expected to enhance Petrichor's ability to navigate the complex landscape of healthcare investments, marrying operational excellence with innovative practices. His profound understanding of the market will assist in guiding emerging companies through various critical stages of their development.

Beyond his significant contributions to the life sciences field, Sekhri also has a passion for the arts. He serves as Chairman of the Board for Young Concert Artists and is an advisory member of the New York Philharmonic, reflecting his broad interests and commitment to community engagement.

About Petrichor

Petrichor has established its credentials as a vital partner for healthcare managers and businesses, tailoring investment strategies that meet the specific needs of its partners. To date, the firm has completed over 125 investments, totaling more than $6 billion, indicating solid confidence in its selection of investment opportunities. Its deep in-house knowledge of healthcare products and services further affirms its status as a strategic ally to emerging firms in the sector.

For more information on Petrichor and its commitment to supporting healthcare innovation, you can visit their official website at petrichorcap.com.